A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

Key Who May Qualify: Part 1 (Healthy participants) - Healthy male participants and female participants of non-childbearing potential between 18-55 years of age - In good health as determined by the investigator's assessment of medical history, physical examination, vital signs, ECG, and laboratory tests - Participants must weigh at least 50 kg at screening and first baseline (admission) and must have a body mass index (BMI) within the range of 18.0-32.0 kg/m2 inclusive. Part 2 (Sickle Cell Disease) \- Male and female participants with a diagnosis of sickle cell disease Key Who Should NOT Join This Trial: Part 1 (Healthy participants) - QTcF ≥ 450 msec (as a mean value of triplicates) - History of arrhythmias - History of significant illness which has not resolved within two (2) weeks prior to initial dosing - Women of child-bearing potential (WOCBP) Part 2 (Sickle Cell Disease) - Current use of hydroxyurea/hydroxycarbamide (HU/HC) - QTcF ≥ 450 msec (as a mean value of triplicates) - History of arrhythmias Other protocol-defined inclusion/exclusion criteria may apply. Always talk to your doctor about whether this trial is right for you.